Summary We investigated the effect of c-myb antisense phosphorothioate oligodeoxynucleotides [(S)ODNs] and cisplatin (CDDP) combination on the human colon carcinoma cell line LoVo Dx both in vitro and in nude mice bearing LoVo Dx solid tumour. We show that antisense (S)ODN treatment decreases c-myb mRNA and protein expression, induces growth arrest in the GI phase of the cell cycle, and inhibits cell proliferation. In vivo treatment with c-myb antisense (S)ODNs results in a reduction in tumour growth. A greater inhibition of cell proliferation in vitro and a higher increase of tumour growth inhibition and growth delay in vivo were obtained with the combination of (S)ODNs and CDDP than when the two agents were administered separately. This comparative study, using the same tumour cell line in vitro and in vivo, suggests that c-myb antisense (S)ODNs might be useful in the therapy of colon cancer in combination with antineoplastic drugs.
The potential use of antisense oligodeoxynucleotides (ODNs) as therapeutic agents in cancer treatment has recently attracted considerable interest. As aberrant expression of growth-promoting genes contributes to the growth advantage of tumour cells, targeting such genes with antisense ODNs might be useful in controlling the abnormal proliferation of cancer cells (Calabretta, 1991) . Indeed, ODNs complementary to oncogene-encoded mRNAs can inhibit proliferation of tumour cell lines (Yokoyama and Imamoto, 1987; Negroni et al., 1991; Raschell'a et al., 1982) . In this regard, we previously demonstrated that an oligodeoxynucleotide complementary to the messenger RNA of c-myb proto-oncogene inhibits in vitro cell growth of a human promyelocytic leukaemia cell line (Citro et al., 1992) .
The c-myb proto-oncogene encodes a DNA-binding protein with transactivation properties that plays an important regulatory role in cell proliferation and differentiation (Shen-Ong, 1990 ). Expression of c-myb was first detected in haematopoietic cells (Shen-Ong, 1990 ) and subsequently in several human solid tumours, particularly in those originating in colon mucosa (Alitalo et al., 1984; Torelli et al., 1987; Ramsay et al., 1992) . It was then demonstrated that c-myb expression is important not only in haematopoietic proliferation and differentiation, but also in the proliferation of nonhaematopoietic cells (Calabretta and Nicolaides, 1992) , suggesting a more general role than previously thought. By comparing normal, dysplastic and malignant colon tissue samples from the same patient, it was found that c-myb expression is higher in colonic tumours than in normal mucosa (Torelli et al., 1987; Ramsey et al., 1992) . This suggests that c-myb may play a role in the malignant transformation of colonic mucosa and that inhibition of cmyb expression may supress, to some extent, proliferation of neoplastic cells. Indeed, c-myb antisense ODNs have already been used to inhibit cell proliferation in colon cancer lines.
However, only a partial suppression of cell proliferation was observed (Melani et al., 1991) , perhaps reflecting the accumulation of alterations in the structure and function of several oncogenes and anti-oncogenes during tumorigenic conversion of normal colonic mucosa (Fearon and Vogelstein, 1990 ). Accordingly, complete suppression of tumour cell proliferation may require inhibition of multiple growthpromoting genes. Alternatively, the combination of oncogene-targeted ODNs with standard cytotoxic drugs might represent a useful therapeutic approach to improving cancer treatment. Only a few reports have so far concentrated on the potentiating effect of antisense ODNs targeting growthpromoting genes on chemotherapeutic drugs (Prins et al., 1993; Nieborowska-Skorska et al., 1994) .
With the aim of obtaining information that may lead to an improved use of (S)ODNs in clinical trials, here we evaluated the efficacy of the combination of c-myb antisense (S)ODNs with an antineoplastic drug on the LoVo Dx human colon carcinoma cell line in vitro and in vivo. For our study, we chose the LoVo Dx model because, if compared with the LoVo parental cell line, it presents a higher level of c-myb expression (Melani et al., 1991) . Specifically, we investigated whether the inhibition of a growth-promoting gene such as cmyb affected the antineoplastic activity of cisplatin (CDDP), a chemotherapeutic agent widely used in the treatment of several solid human malignancies (Rosenberg, 1985) , including colon carcinoma (Scheithauer et al., 1991; Rowinsky et al., 1991) .
Materials and methods

Cell culture
The LoVo Dx cell line resistant to doxorubicin (Dx) was derived from a human colon adenocarcinoma (Grandi et al., 1986 Phosphorothioate oligodeoxynucleotides (supplied from Lynx Therapeutics, Hayward, CA, USA), were resuspended at 5 mg ml-' in sterile saline solution and stored at -20°C in small aliquots. (S)ODNs corresponding to the translation initiation region of the human c-myb mRNA codons 2 -7, were used for in vitro and in vivo studies. The sequences derived from the human c-myb cDNA (Majello et al., 1986) , were 5'-GCC CGA AGA CCC CGG CAC-3' and 5'-GTG CCG GGG TCT TCG GGC-3' for the c-myb sense and antisense 18 mer (S)ODNs respectively. In additional in vitro experiments, we used a c-myb antisense ODN corresponding to codons 2-6 and two three-base-mismatched derivatives (5'-GTC CTG GGG TCG TCG-3' and 5'-GTG CGG GTG CCC TTCG-3' respectively).
In vitro (S)ODNs and CDDP treatment Cell proliferation studies Approximately 1 x 104 cells were seeded in 24-well plates (Costar) and treated every 24 h with 10 ,UM c-myb sense or antisense (S)ODN for 3 consecutive days. Control cells were cultured in the same conditions without (S)ODNs. For CDDP and (S)ODN combinations, CDDP (at the dose of 2 Mug ml-') was added 24 h after seeding the cells in culture and was removed 2 h later. c-myb sense or antisense (S)ODNs (10 Mm) were added to the culture medium for 3 consecutive days after CDDP treatment. Quadruplicate samples from each treatment were harvested with 0.05% trypsin-EDTA solution; cell counts (Coulter Counter model ZM, Kontron) and viability (trypan blue dye exclusion) were determined daily until day 10 of culture.
Isobologram analysis Approximately 1 x 104 cells were seeded in 24-well plates (Costar) and after 24 h were treated as follows: (a) CDDP at doses ranging from 1 to 6 Mg ml-' for 2 h; (b) c-myb antisense (S)ODNs at doses ranging from 2.5 h to 20 pM every 24 h for 3 consecutive days; (c) CDDP at 1 and 2 Mg ml-' for 2h followed by c-myb antisense at 5 and 10 ,M every 24 h for 3 consecutive days. On days 5, 8 and 10 of cell culture, quadruplicate samples from each treatment were harvested as above, counted and assayed for viability. Then, isobologram analysis was performed to assess the nature of the interaction between the two agents.
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR) analyses Total RNA was extracted from LoVo Dx cells by the acid guanidium thiocyanate -phenol -chloroform technique (Chomczynski and Sacchi, 1987 (Amersham) . Filters were blocked with 2% non-fat skim milk in TBS (20 mM Tris pH 8.2, 137 mM sodium chloride) for 1 h at room temperature. Anti-Mybspecific monoclonal antibody (UBI 05-175) was used at 1:1000 dilution in 1% non-fat skimmed milk in TBS containing 0.5% Tween 20 for 2.5 h, washed three times for 20 min with TBS and detected by horseradish peroxidase-conjugated anti-mouse antibody (Bio-Rad, 172-1011, Richmond, CA, USA) according to the manufacturer's instructions. After three washings in TBS containing 0.5% Tween 20, filters were incubated in a luminol-based detection solution for 1 min and then exposed for various times to Kodak X-OMAT AR film. To assess protein amounts transferred into nitrocellulose membrane, after stripping the c-Myb antibody, fl-actin, used as control, was detected with an anti-human fl-actin MAb (clone JLA20, Oncogene Science, NY, USA). Myb protein levels were quantified by scanning the autoradiography films with a gel densitometer scanner (Model 620, Bio Rad) and normalised to ,B-actin levels.
Cell cycle analysis On days 1, 3 6 and 9 of cell culture, untreated, sense-or antisense (S)ODN-treated cells were washed, harvested, pooled and centrifuged at 130 g for 10 min. After two washings in cold phosphate-buffered saline (PBS), cells were fixed in 50% acetone-methanol (1:4, v/v) in PBS at 4°C for at least 1 h before flow cytometric analysis. Approximately 2 x 105 fixed cells were stained with 400 MI of a solution containing 75 kU ml-' RNAase (Sigma, St Louis, MO, USA) and 50 Mg ml-' propidium iodide (Sigma) for 30 min at room temperature. After filtration through an 80 gM nylon mesh, DNA content of the samples was measured using a FACScan cytofluorimeter (Becton Dickinson Sunnyvale, CA, USA). For each sample, 20 000 events were analysed in duplicate. The percentage of cells in the different cell cycle phases was estimated by applying a mathematical model (Fox, 1980) to the histograms by means of a Becton Dickinson software package.
In vivo experiments Athymic CD-1 nu/nu mice, 5-6 weeks old, were purchased from the Charles River Laboratories (Calco, Italy). Mice were kept in a laminar air-flow cabinet under specific pathogen-free conditions. The LoVo Dx colon carcinoma was established as a solid intramuscular tumour by injecting 0.2 ml of a suspension containing 2 x 106 viable cells in the leg muscle with the tumour being maintained by serial passages in vivo at 3 week intervals. We chose the intramuscular implant because it produces a more homogeneous tumour take and tumour growth than the subcutaneous implant. In fact, 7-8 days after cell injection, a tumour mass was evident in 100% of injected mice. Singlecell suspensions were prepared from tumours by enzymatic digestion as previously described (Arancia et al., 1991 (Figure 2a) . The 18-mer c-myb (S)ODNs had no significant effect on LoVo Dx cell survival, in the same experimental conditions. A clonogenic assay performed at each day of growth, starting from days 2-10, demonstrated that cell survival was not affected in the case of c-myb sense treatment whereas after c-myb antisense treatment the decrease in cell survival was 25% (on day 2), 30% (on day 5) and 30% (on day 10) (data not shown).
Additional experiments were performed with a 15-mer c-myb antisense ODN and with two three-base-mismatched derivatives, one of which included (see Materials and methods) the 4-G motif reported to non-specifically inhibit proliferation of certain cell lines (Yaswen et al., 1993; Burgess et al., 1995) . The c-myb antisense (S)ODNs inhibited LoVo Dx cell proliferation, whereas neither mismatched sequence had appreciable effects (Figure 2b ). Cell cycle phases distribution of LoVo Dx cells exposed to sense or antisense c-myb (S)ODNs was evaluated by flow cytometry (Figure 3) . The analysis was performed on days 1, 3, 6 and 9 of growth in liquid culture. Treatment with c-myb antisense (S)ODNs resulted in accumulation of cells in the G, phase of the cell cycle with a simultaneous reduction of cells in the S-phase, already detectable on the third day of culture. No clear effect on the G2 + M compartment was observed. Cell cycle distribution of LoVo Dx cells treated with c-myb sense (S)ODNs was indistinguishable from that of untreated cells (data not shown). Together, these results indicate that treatment with c-myb antisense (S)ODNs induces inhibition of cell proliferation, evident only several days after exposure to the (S)ODNs.
Effect of c-myb antisense (S)ODNs and DDP treatment on Lo Vo Dx cell proliferation and c-myb mRNA levels Figure 4a shows the effect of CDDP and c-myb antisense (S)ODNs given alone or in combination on LoVo Dx cell proliferation. Incubation for 2 h with CDDP followed by a 3 day c-myb antisense (S)ODN treatment led to an increase in sensitivity of LoVo Dx cells to CDDP. In fact, as evaluated after 6-8 days of culture, the (S)ODN/CDDP combination 390
produced an approximately 80% inhibition of cell proliferation whereas CDDP and (S)ODNs, used individually, produced approximately a 50% and 55% inhibition respectively. The antiproliferative effect of the various compounds was correlated with levels of c-myb mRNA, detected by RT-PCR. Only the treatment with c-myb antisense (S)ODNs, individually or in combination with CDDP, induced a decrement of c-myb mRNA levels ( Figure 4b ).
Isobologram analysis
To define the type of the interaction and the interaction index (Berembaum, 1981 (Berembaum, , 1985 between CDDP and c-myb
Growth days 10 b antisense (S)ODNs in combination we determined, initially, the effect of increasing doses of CDDP (Figure 5a ) and c-myb antisense (S)ODNs (Figure 5b) Single doses of CDDP and c-myb antisense (S)ODNs producing the same effect on cell growth at the same day, in terms of mean cell number, were determined, interpolating the results from Figure 5a and b. When the dose of the agent used alone and producing the same effect of the combination exceeds the highest experimental dose, this maximum dose value is used to calculate the interaction index. Table I shows the interaction index for the combination CDDP/c-myb antisense calculated as above from the data reported in Figure 5c . According to Berembaum (1981) , the evaluation of the type and level of interaction among agents can be approached in terms of interaction index (I), defined as the sum of the ratios between dosages of the agent which, when used in combination or alone, induces the same effect in terms of cell survival or growth. The interaction index can assume the following values:
I < 1 indicates synergistic interaction; I = 1 indicates additive interaction; I> 1 indicates antagonistic interaction. As the interaction index values reported in Table I ranging around 1 and taking into account the uncertainty related to the experimental data (Gentile et al., 1992) , the interaction index value for additivity can be included in the range 0.8-1.2. Therefore, from our experimental data we can conclude (0) We selected c-myb antisense (S)ODNs corresponding either to codons 2-7 or 2-6 as the region immediately downstream from the initiation codon is commonly targeted in antisense experiments and as we were previously able to inhibit proliferation of a human leukaemia cell line by targeting the same mRNA region (Citro et al., 1992) . Here, we demonstrated that c-myb expression plays an important role in LoVo Dx cell proliferation, both in vitro and in vivo. We observed that a down-regulation of c-Myb protein is evident as early as 30 h after the beginning of treatment when cell proliferation was only marginally affected. The early down regulation of c-Myb protein levels after antisense (S)ODN treatment most likely reflects the short half-life (30-60 min) of c-Myb mRNA and protein (Thiele et al., 1988; Lipsick and Boyle, 1987) , and is consistent with the interpretation that the down-regulation of c-myb protein expression is not the result but the cause of the reduction in cell proliferation.
We also found that in vivo treatment of LoVo Dx tumour with c-myb antisense (S)ODNs reduces the tumour growth, in terms of both tumour weight inhibition and tumour growth delay. These data agree with those of other authors, confirming the in vivo antiproliferative effect of c-myb antisense (S)ODNs and its potential usefulness for the systemic treatment of solid and non-solid tumours (Ratajczak et Hijiya et al., 1994) . In particular, our results are similar to those obtained in the experimental melanoma model (Hijiya et al., 1994) ; whereas a higher response was reported using a mouse model of human leukaemia (Ratajczak et al., 1992) , probably reflecting cell type differences or the higher sensitivity of haematopoietic cells to c-myb deprivation. As demonstrated by the isobologram analysis, the combination of c-myb antisense (S)ODNs with CDDP produces an additive effect on LoVo Dx cell proliferation in vitro, if compared with the effect produced by the two agents given alone. In addition, these in vitro results are supported by the in vivo data, where a significant difference between the tumour weight inhibition in mice treated with the combination CDDP/c-myb antisense and the tumour weight inhibition in mice treated with the two agents given separately was observed.
Most probably, CDDP exerted its antiproliferative activity independently of a direct effect on c-myb expression, as c-myb mRNA levels were not down-regulated in cultures treated with CDDP alone (Figure 4b) . Incidentally, this finding is an additional proof that the down-regulation of c-myb expression is a specific consequence of the treatment with c-myb antisense (S)ODNs, and not of the inhibition of cell proliferation per se. It has already been demonstrated that the degree of resistance to CDDP correlates directly with the level of c-myc expression (Sklar and Prochownik, 1991) and that the treatment with cmyc antisense ODNs leads to an increased CDDP sensitivity in a small-cell lung carcinoma line that shows c-myc mRNA and protein overexpression, this effect not being evident in CDDP-sensitive cells (Prins et al., 1993) . It has also been demonstrated that the expression of a fos ribozyme, which reduces Fos protein synthesis, enhances the sensitivity of a human ovarian cancer line resistant to CDDP to antineoplastic agents, including cisplatin (Funato, 1994) . Moreover, the combination of conventional chemotherapeutic agents and antisense against ber/abl or c-myb or the combination of antitumour cytotoxic T lymphocytes and c-myb antisense oligodeoxynucleotides has been reported to be highly effective in killing tumour cells (Nieborowska-Skorska et al., 1994) . Thus, the level of expression of genes involved in cell proliferation (e.g. c-myc, c-myb, c-fos) might affect the therapeutic response of malignant cells.
In conclusion, our data support the potential use of (S)ODNs in combination with antineoplastic agents to improve cancer management.
Furthermore, it is noteworthy that, even if the two drugs are only additive in their lethal effects, as the toxic effects are less than additive a net gain in the therapeutic index may be achieved that is clinically exploitable (Drewinko et al., 1976) . Abbreviations CDDP, cisplatin; (S)ODNs, phosphorothioate oligodeoxynucleotides; RT-PCR, reverse transcriptase-polymerase chain reaction; TWI, tumour weight inhibition; T-C, tumour growth delay.
